Twin Tree Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-13,500
| Closed | -$2.07M | – | 1391 |
|
|
2025
Q3 | $2.07M | Buy |
+13,500
| New | +$2.04M | 0.01% | 1032 |
|
|
2024
Q2 | – | Sell |
-49,000
| Closed | -$6.64M | – | 1341 |
|
|
2024
Q1 | $6.64M | Sell |
49,000
-599,000
| -92% | -$79.3M | 0.01% | 744 |
|
|
2023
Q4 | $87.3M | Sell |
648,000
-50,700
| -7% | -$6.59M | 0.17% | 108 |
|
|
2023
Q3 | $94.6M | Buy |
+698,700
| New | +$95.4M | 0.21% | 84 |
|
|
2023
Q1 | – | Sell |
-517,650
| Closed | -$70.2M | – | 1275 |
|
|
2022
Q4 | $70.2M | Sell |
517,650
-138,350
| -21% | -$17.4M | 0.15% | 121 |
|
|
2022
Q3 | $72M | Sell |
656,000
-510,900
| -44% | -$64.8M | 0.14% | 113 |
|
|
2022
Q2 | $154M | Buy |
1,166,900
+320,100
| +38% | +$42M | 0.25% | 35 |
|
|
2022
Q1 | $112M | Buy |
846,800
+516,700
| +157% | +$62M | 0.18% | 77 |
|
|
2021
Q4 | $38.5M | Sell |
330,100
-339,300
| -51% | -$39.9M | 0.08% | 226 |
|
|
2021
Q3 | $80.4M | Buy |
669,400
+150,550
| +29% | +$17.5M | 0.18% | 94 |
|
|
2021
Q2 | $62.2M | Buy |
518,850
+346,050
| +200% | +$38M | 0.17% | 122 |
|
|
2021
Q1 | $17.2M | Buy |
172,800
+122,950
| +247% | +$12.4M | 0.06% | 314 |
|
|
2020
Q4 | $4.98M | Hold |
49,850
| – | – | 0.02% | 628 |
|
|
2020
Q3 | $5.46M | Buy |
+49,850
| New | +$5.54M | 0.02% | 551 |
|
|
2020
Q1 | – | Sell |
-8,000
| Closed | -$798K | – | 1346 |
|
|
2019
Q4 | $798K | Buy |
+8,000
| New | +$753K | ﹤0.01% | 895 |
|
|
2018
Q4 | – | Sell |
-50,350
| Closed | -$3.98M | – | 1328 |
|
|
2018
Q3 | $3.98M | Buy |
+50,350
| New | +$3.81M | 0.03% | 442 |
|
|
2018
Q2 | – | Sell |
-35,550
| Closed | -$2.49M | – | 1134 |
|
|
2018
Q1 | $2.49M | Sell |
35,550
-96,300
| -73% | -$6.67M | 0.02% | 475 |
|
|
2017
Q4 | $9.15M | Sell |
131,850
-277,200
| -68% | -$18.7M | 0.07% | 258 |
|
|
2017
Q3 | $27.7M | Buy |
409,050
+348,200
| +572% | +$22M | 0.22% | 90 |
|
|
2017
Q2 | $4.15M | Buy |
60,850
+56,850
| +1,421% | +$3.71M | 0.03% | 405 |
|
|
2017
Q1 | $249K | Buy |
+4,000
| New | +$233K | ﹤0.01% | 827 |
|
|
2015
Q4 | – | Sell |
-13,100
| Closed | -$834K | – | 1380 |
|
|
2015
Q3 | $834K | Sell |
13,100
-25,800
| -66% | -$1.7M | 0.02% | 603 |
|
|
2015
Q2 | $2.48M | Sell |
38,900
-800
| -2% | -$54.8K | 0.06% | 344 |
|
|
2015
Q1 | $2.72M | Buy |
39,700
+35,700
| +893% | +$2.48M | 0.07% | 304 |
|
|
2014
Q4 | $282K | Sell |
4,000
-35,500
| -90% | -$2.54M | 0.01% | 860 |
|
|
2014
Q3 | $2.82M | Sell |
39,500
-117,900
| -75% | -$8.63M | 0.08% | 274 |
|
|
2014
Q2 | $11.7M | Sell |
157,400
-65,100
| -29% | -$4.71M | 0.26% | 55 |
|
|
2014
Q1 | $14.4M | Buy |
222,500
+58,100
| +35% | +$3.75M | 0.29% | 33 |
|
|
2013
Q4 | $9.76M | Buy |
164,400
+161,300
| +5,203% | +$8.76M | 0.23% | 63 |
|
|
2013
Q3 | $161K | Hold |
3,100
| – | – | 0.01% | 726 |
|
|
2013
Q2 | $147K | Buy |
+3,100
| New | +$158K | 0.01% | 716 |
|
Other funds holding AZN
IA
VCM
VAM
Twin Tree Management's AZN Position: Q1 2026 in Review
Twin Tree Management increased its AstraZeneca (AZN) stake by 16% in Q1 2026, buying an estimated $309K and bringing the position to 11,420 shares worth $2.25M. The position accounts for 0.05% of the portfolio, ranked #436.
Twin Tree Management first reported a position in AZN in Q1 2014 and has held it in 36 quarters since. The position peaked at $37.8M in Q3 2022. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Twin Tree Management held 11,420 shares of AstraZeneca worth $2.25M as of Q1 2026.
- Twin Tree Management bought 1,604 AstraZeneca shares in Q1 2026, an estimated $309K.
- AstraZeneca made up 0.05% of Twin Tree Management's portfolio in Q1 2026, its #436 holding.
- Twin Tree Management first reported a position in AstraZeneca in Q1 2014 and has held it in 36 quarters since.
- Twin Tree Management's AstraZeneca position peaked at $37.8M in Q3 2022.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Twin Tree Management's 13F filing for Q1 2026, filed 14 May 2026.